Evidence map›Paper›PMID 39025917›Full record

ArticleBone marrow transplantation2024

Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.

C Ganzel, Y Wang, K Roopcharan, Z Sun, J M Rowe, H F Fernandez, E M Paietta, S M Luger, H M Lazarus, L D Cripe and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

C GanzelFaculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. ganzelc@szmc.org.il.ORCID http://orcid.org/0000-0002-1722-4807
Y WangDana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA, USA.
K RoopcharanDana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA, USA.
Z SunDana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA, USA.
J M RoweDepartment of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
H F FernandezMoffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System, Pembroke Pines, FL, USA.
E M PaiettaAlbert Einstein College of Medicine, New York, NY, USA.
S M LugerDivision of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
H M LazarusCase Western Reserve University School of Medicine, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-1159-5607
L D CripeIndiana University Simon Cancer Center, Indianapolis, IN, USA.
D DouerDepartment of Hematology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
P H WiernikCancer Research Foundation, Chappaqua, NY, USA.ORCID http://orcid.org/0000-0003-1473-813X
M S TallmanMemorial Sloan Kettering Cancer Center, New York, NY, USA.
M R LitzowDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-9816-6302

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39025917
PMCPMC11368803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.